Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for January 9, 2026 [1][3]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates, overstated the quality of the supply chain, and provided materially false information about the company's business and prospects [3]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission on July 22, 2025, Telix's American Depositary Shares (ADSs) fell more than 13% over two trading sessions [4]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, leading to a further decline of over 21% in the price of Telix's ADSs [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is typical of class members, and any member of the class can move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Telix's conduct, including whistleblowers and former employees, to contact the firm [6].
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX